Caribou Biosciences Reports Wider Q2 Loss Amid Increased R&D Spending

Caribou Biosciences reported a net loss of $54.1 million in Q2 2025, compared to $37.7 million in Q2 2024. The company's revenue from licensing and collaboration decreased to $2.7 million from $3.5 million YoY, while operating expenses increased due to impairment charges and R&D efforts. Despite financial challenges, Caribou Biosciences maintains a cash position of $25.2 million and aims to leverage its CRISPR technology to achieve regulatory approval and commercialization of its product candidates.

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has reported its second-quarter 2025 financial results and provided a business update for its oncology clinical programs CB-010 and CB-011. The company reported a net loss of $54.1 million, compared to $37.7 million in Q2 2024. Revenue from licensing and collaboration agreements decreased to $2.7 million from $3.5 million year-over-year (YoY), while operating expenses increased due to impairment charges and research and development (R&D) efforts.

Caribou Biosciences maintained a robust cash position of $183.9 million as of June 30, 2025, with expectations that this will be sufficient to fund its current operating plan through the second half of 2027. The company's cash position includes cash, cash equivalents, and marketable securities.

The company's R&D expenses were $27.7 million for the three months ended June 30, 2025, compared to $35.5 million for the same period in 2024. This decrease was primarily due to strategic pipeline prioritization and related workforce reduction, as well as lower costs associated with ongoing clinical trials.

Caribou Biosciences also reported general and administrative (G&A) expenses of $10.4 million for the three months ended June 30, 2025, compared to $11.5 million for the same period in 2024. The decrease was primarily due to reduced personnel-related expenses, including stock-based compensation, and lower patent prosecution and maintenance costs.

The company's non-recurring, non-cash impairment charges were $21.3 million for the three months ended June 30, 2025, including charges related to strategic pipeline prioritization and an impairment of the company's stock investment in a private company.

Despite the financial challenges, Caribou Biosciences remains optimistic about its clinical programs. The company expects to report robust datasets from both CB-010 and CB-011 in the second half of 2025. CB-010, an allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma, completed enrollment of a 20-patient confirmatory cohort in the ANTLER Phase 1 clinical trial. CB-011, an allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma, completed planned enrollment for the dose escalation portion of the CaMMouflage Phase 1 clinical trial.

Caribou Biosciences aims to leverage its CRISPR technology to achieve regulatory approval and commercialization of its product candidates. The company believes that its off-the-shelf CAR-T cell therapies have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

References:
[1] https://www.globenewswire.com/news-release/2025/08/12/3132134/0/en/Caribou-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html